Search clinical trials for: PEP503

Total 56 results

Nanobiotix
PharmaEngine

Completed

NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall

Adult Soft Tissue Sarcoma

Philippines, Norway, Spain, France, Belgium, Hungary, Germany, Italy, Australia, Hong Kong, Poland, Romania, South Africa
PharmaEngine

Unknown

Two-Stage Study to Assess the Efficacy and Safety of 12 Weeks of Treatment With PEP03 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

COPD

Taiwan
PharmaEngine

Terminated

A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma

Taiwan
Peplin
TKL Research, Inc.

Completed

A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)

Actinic Keratosis

United States, Australia
Peplin

Completed

A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Actinic Keratosis

United States, Australia
Peplin

Completed

Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel

Keratosis

United States
Peplin

Completed

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses

Actinic Keratosis

Australia
Peplin

Completed

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma

Basal Cell Carcinoma

Australia
Peplin

Completed

To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC

Superficial Basal Cell Carcinoma

United States
Peplin

Completed

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

Actinic Keratosis

United States
Peplin

Withdrawn

The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)

Warts

Australia
Peplin

Completed

Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005

Actinic Keratoses

Australia
Peplin

Completed

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ

Carcinoma, Squamous Cell

Australia
Peplin

Completed

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma

Basal Cell Carcinoma

Australia
Peplin
LEO Pharma

Completed

PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects

Healthy | Actinic Keratosis

United States
Peplin
Omnicare Clinical Research

Completed

A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand

Actinic Keratosis

United States
Peplin

Completed

Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2

Actinic Keratosis

United States, Australia
Peplin

Completed

A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

Actinic Keratosis

United States
Peplin

Completed

Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin

Photo-damage

Australia
Peplin

Completed

A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

Actinic Keratosis

United States
Peplin

Completed

Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis

Seborrheic Keratosis

Australia
PharmaEngine

Not yet recruiting

A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor
Icahn School of Medicine at Mount Sinai
LEO Pharma

Completed

Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses

Actinic Keratoses

United States
Peplin

Completed

A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Actinic Keratosis

United States, Australia
LEO Pharma

Completed

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology

Actinic Keratosis

Germany
LEO Pharma

Completed

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy

Actinic Keratosis

Germany
Peplin

Completed

Study to Determine the Sensitizing Potential of PEP005 Topical Gel in Healthy Volunteers Using a Repeat Insult Patch Test Design

Healthy

United States
Peplin

Completed

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Actinic Keratoses

United States, Australia
Peplin

Completed

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Actinic Keratoses

United States
Peplin

Completed

A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Actinic Keratosis

United States, Australia
Peplin

Completed

A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis

Actinic Keratosis

United States
PharmaEngine

Recruiting

A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer

Acute Myeloid Leukemia | Lymphoma, Mantle-Cell

Australia
Peplin

Completed

A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel

Actinic Keratoses

Australia, New Zealand
Peplin

Completed

PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities

Superficial Basal Cell Carcinoma

Australia
Futura Medical Developments Ltd.
Richmond Pharmacology Limited

Completed

Study to Determine the Effect of a Newly Formulated Tetracaine Product PET500 on Penile Skin Sensation (FM48)

Healthy Volunteers
PharmaEngine

Completed

Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy

Metastatic Colorectal Cancer

Taiwan
Millennium Pharmaceuticals, Inc.

Completed

A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease

Digestive System Disease

United States
PharmaEngine

Terminated

A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer

Rectal Cancer

Taiwan
Hamad Medical Corporation

Completed

Management of Tunneled Catheter Thrombosis in Hemodialysis Patients: Prospective Study From Qatar

Hemodialysis, Tunneled Catheter, Qatar

Qatar
Medtronic - MITG

Completed

Comparison Study of Surgical Staplers for the Treatment of Hemorrhoids (HEMOSTASIS)

Hemorrhoids

United States
Bausch & Lomb Incorporated

Completed

Biotrue ONEday Contact Lenses With EPG03 Packaging Solution Compared to Biotrue ONEday Contact Lenses

Contact Lens Wearer

United States
PharmaEngine

Completed

Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer

Pancreatic Neoplasms

Taiwan, United States
Imperial College Healthcare NHS Trust

Completed

Taurolidine in Haemodialysis Catheter Related Bacteraemia

Catheter-Related Infections | Renal Dialysis

United Kingdom
Medical University of Vienna

Completed

Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction

End-stage Renal Disease | Catheter Infections

Austria
PharmaEngine

Completed

Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Stomach Neoplasms | Esophageal Neoplasms

Korea, Republic of, Spain, Taiwan, Bosnia and Herzegovina, United Kingdom, Croatia
Emory University
Ipsen; Taiho Oncology, Inc.

Recruiting

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Gastric Adenocarcinoma | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Colorectal Adenocarcinoma | Stage IV Gastric Cancer | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Stage... and other conditions

United States
Merrimack Pharmaceuticals

Completed

Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer (NAPOLI-1)

Metastatic Pancreatic Cancer

United States, France, United Kingdom, Germany, Taiwan, Spain, Argentina, South Africa, Korea, Republic of, Canada, Brazil, Czech Republic, Hungary, Italy, Australia
PharmaEngine

Completed

A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors

Solid Tumor
University of Southern California
National Cancer Institute (NCI); Ipsen

Withdrawn

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Locally Advanced Unresectable Gastric Adenocarcinoma | Metastatic Unresectable Gastric Adenocarcinoma

United States
Institut de Recherches Internationales Servier

Not yet recruiting

Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas

Metastatic Adenocarcinoma of the Pancreas

Japan

3

Subscribe